Global Cystic Fibrosis Therapeutics Market 2016-2020

SKU ID : TNV-IRTNTR10588 10288302

Publishing Date : 05-Oct-2016

No. of pages : 80


  • About Cystic Fibrosis

    Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited, chronic disease and is progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The primary symptoms of cystic fibrosis include breathing difficulties, high salt content in the sweat, and secretion of abnormally viscous mucus. The principal indicators of cystic fibrosis in patients are pancreatic insufficiency, pancreatitis, chronic bronchitis, adolescent diabetes, male sterility, and very rarely liver cirrhosis or intestinal obstruction. The most usual forms of cystic fibrosis are those with respiratory complications, difficulties related to digestion, and anomalies in height and growth. The mortality and morbidity of a patient are dependent on the degree of bronchopulmonary involvement.

    Technavio’s analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 31.9% during the period 2016-2020.

    Covered in this report
    The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2016-2020. The report has taken into consideration the revenue generated by the vendors in the PET packaging market for packaging of different goods.

    The market is divided into the following segments based on geography:
    • Americas
    • APAC
    • EMEA

    Technavio's report, Global Cystic Fibrosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

    Key vendors
    • AbbVie
    • F. Hoffmann-La Roche
    • Gilead Sciences
    • Novartis
    • Vertex Pharmaceuticals

    Other prominent vendors
    • Advanced Inhalation Therapies (AIT)
    • Alaxia SAS
    • Alcresta Therapeutics
    • AlgiPharma
    • Allergan
    • Anthera
    • AstraZeneca
    • Bayer
    • Celtaxsys
    • Chiesi Farmaceutici
    • Corbus Pharmaceuticals
    • Cyclacel Pharmaceuticals
    • Digestive Care
    • Galapagos
    • Grifols
    • Insmed Incorporated
    • Kamada
    • Nivalis Therapeutics
    • Novoteris
    • Parion Sciences
    • Pharmaxis
    • ProQR Therapeutics
    • Protalix Biotherapeutics
    • Proteostasis Therapeutics
    • PTC Therapeutics
    • Pulmatrix
    • Savara
    • SolAeroMed
    • Vectura

    Market driver
    • Special regulatory designations for drugs
    • For a full, detailed list, view our report

    Market challenge
    • Discontinuation of drugs from development
    • For a full, detailed list, view our report

    Market trend
    • Co-pay and assistance programs by vendors
    • For a full, detailed list, view our report

    Key questions answered in this report
    • What will the market size be in 2020 and what will the growth rate be?
    • What are the key market trends?
    • What is driving this market?
    • What are the challenges to market growth?
    • Who are the key vendors in this market space?
    • What are the market opportunities and threats faced by the key vendors?
    • What are the strengths and weaknesses of the key vendors?

    You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.